NBRV News and Press, Nabriva Therapeutics plc From 09/09/19

DUBLIN, Ireland, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the oral and intravenous (IV) formu...

Nabriva Therapeutics (NASDAQ: NBRV ) has earned a $5M milestone payment under its licensing agreement with Sinovant Sciences related to the U.S. regulatory approval of Xenlata (lefamulin). More news on: Nabriva Therapeutics plc, Healthcare stocks news, Read more ...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Nabriva ha...

DUBLIN, Ireland, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will present data at the ASM/ESC...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Execu...

Nabriva Therapeutics plc (NASDAQ: NBRV ) +23% . More news on: Nabriva Therapeutics plc, VIVUS, Inc., Seadrill Limited, Stocks on the move, Read more ...

August 20, 2019 Palm Beach, FL –August 20, 2019 – Cancer drug market revenues have been steadily rising in the past few years and all indicators predict that they will continue to rise over the next several years. According to industry sources, in 20118 oncology ...

Gainers:  NBRV   +20.3% . VNET   +13.2% . BIDU   +9.1% . YUMA   +9.0%.  MRNA   +7.4% . More news on: Nabriva Therapeutics plc, 21Vianet Group, Inc., Baidu, Inc., Stocks on the move, , News on ETFs Read more ...

First New IV and Oral Antibiotic with a Novel Mechanism of Action Approved in Nearly Two Decades Provides Critically Needed Treatment Option for Adult Patients with CABP   XENLETA Expected to be Available mid-September 2019 Conference call and webcast today at 4:30 p.m. ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...